# AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM

> **NCT05100641** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Aivita Biomedical, Inc.** · enrollment: 672 (estimated)

## Conditions studied

- Primary Glioblastoma

## Interventions

- **BIOLOGICAL:** AV-GBM-1
- **BIOLOGICAL:** Autologous monocytes

## Key facts

- **NCT ID:** NCT05100641
- **Lead sponsor:** Aivita Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 672 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100641, "AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05100641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*